Nasdaq · CIK 0001941029
ADVB Advanced Biomed Inc.
D
45 / 100
Material weaknesses
2
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
0
Deductions
55
Remediation credit
0
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“(ii) our internal control policy does not have a proper approval mechanism, and our lack of internal controls on performing periodic reviews of user accounts and their level of authorization in the financial systems.”
“The material weaknesses identified relate to (i) our lack of a sufficient number of finance and accounting personnel or sufficiently trained finance and accounting personnel, as well as comprehensive accounting policies in accordance with U.S. GAAP financial reporting;”
“Based on this evaluation, the management concluded that our internal control over financial reporting was ineffective as of June 30, 2026.”
Filings read
- 10-K · 2026-10-13read
- 10-K · 2025-10-08queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.